MedTrace Logo

HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda

NCT01520272 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 376

Last updated 2018-04-05

No results posted yet for this study

Summary

Background:

\- Cervical cancer is one of the leading causes of cancer death in women worldwide and in Uganda. It is caused by the human papillomavirus (HPV). A vaccine against HPV was offered for all 10-year-old girls in the Nakasongola district of Uganda from October 1, 2008, to October 31, 2009. The HPV vaccine requires three doses; however, some girls received only one or two doses. Researchers want to compare vaccine immunogenicity in girls who received all three doses with those who had only one or two doses.

Objectives:

\- To examine the immunogenicity (antibody levels) of girls in Uganda who received only one, two or three doses of HPV vaccine.

Eligibility:

* Girls who will be at least 12 years old by October 31, 2011, and had at least one dose of the HPV vaccine.
* All participants will come from the Nakasongola district of Uganda.

Design:

* Participants will have a physical exam and answer questions about their medical history and HPV risk.
* Participants will provide a single blood sample for testing.
* Treatment and vaccines will not be provided as part of this study. Girls who did not receive all three doses of the HPV vaccine will be given information about the nearest health center. Health centers will provide the missed doses free of charge.

Conditions

  • HPV16 Anitbody Levels Post Vaccination
  • HPV18 Antibody Levels Post Vaccination

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Allan Hildesheim, Ph.D. · National Cancer Institute (NCI)

Eligibility

Min Age
12 Years
Max Age
20 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-02
Completion
2017-06-28

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01520272 on ClinicalTrials.gov